The German pharmaceutical giant yesterday reported a second quarter revenue of €3.2bn (£2.6bn).
In a call yesterday, CEO
The results, however, were not well received by investors, with shares down 10 per cent yesterday morning.
The company said it expects deliveries for its Omicron-adapted vaccine to begin as soon as October.
The CEO explained that "with the current development path, it has generally taken us eight months to produce a new vaccine candidate" to combat new strains of Covid-19.
However, he hopes to trim this time down to "as little as three months".
(c) 2022 City A.M., source